|Videos|September 25, 2021

Dr. Scarlett Gomez discusses prostate genomic testing in a world of precision medicine

“We're increasingly seeing the addition of molecular and genetic tests to guide us in terms of the cancer treatment that we provide our patients,” says Scarlett Gomez, MD, PhD.

In this video, Scarlett Gomez, MD, PhD, discusses the background and findings of the study, “Active surveillance for watchful waiting in clinically low-risk prostate cancer patients in the SEER database with and without an Oncotype DX genomic prostate score assay,” presented at the 2021 American Urological Association Annual Meeting. Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME